Troy Wood Presents at 2024 IMSC Conference in Australia
August 30, 2024
On August 23, 2024, Troy Wood presented “Quality Assurance Using Mass Spectrometry to Analyze Structural Fidelity of Monoclonal Antibodies in HIV-1 Therapeutics” at the International Mass Spectrometry Conference in Melbourne, Australia.
The development of broadly neutralizing antibodies (bNAbs) for the prevention and treatment of HIV-1 infection has gained attention as an alternative to conventional antiretroviral therapy because of their potential for passive immunotherapy and long half-lives. A number of bNAbs targeting the HIV-1 viral envelope are under investigation for their effects on viral suppression in combination. While methods to quantify bNAbs using mass spectrometry are one element of quality assurance, it is also important to validate the structural fidelity of therapeutic antibodies; this includes not only validation of the primary amino acid sequence, but also the presence and location of posttranslational modifications (PTMs), many of which are essential for optimal efficacy of the antibody.
For more information, read the full abstract of Troy’s presentation.
